IMV
$3.32
Imv
$.17
5.40%
IMV
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.08)
Revenue:  $0.05 Mil
Friday
Nov 6
7:05 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, August 12, 2020

What do you expect when IMV reports earnings?
Beat
Meet
Miss

Where is IMV's stock price going from here?
Up
Flat
Down
Stock chart of IMV
Analysts
Summary of analysts' recommendations for IMV
Score
Grade
Pivots
Resistance
$3.77
$3.57
$3.45

$3.25

Support
$3.13
$2.93
$2.81
Tweet
Growth
Description
IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company's pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada.